Valuation: Inovio Pharmaceuticals Inc

Market Cap 330M 300M 277M 252M 472M 30.53B 496M 3.37B 1.34B 16.67B 1.24B 1.21B 52.33B P/E 2026 *
-1.96x
P/E 2027 * -9.96x
Enterprise Value 330M 300M 277M 252M 472M 30.53B 496M 3.37B 1.34B 16.67B 1.24B 1.21B 52.33B EV / Sales 2026 *
944x
EV / Sales 2027 * 3.93x
Free-Float
99.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 09/05/2022
Director of Finance/CFO 62 31/05/2002
Chief Tech/Sci/R&D Officer 60 26/06/2022
Director TitleAgeSince
Chairman 81 02/01/2019
Director/Board Member 69 10/03/2016
Director/Board Member 71 05/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.37%-1.22%+33.67%+175.26% 44B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.90%

Financials

2026 *2027 *
Net sales 349K 318K 293K 267K 500K 32.35M 526K 3.57M 1.42M 17.67M 1.31M 1.28M 55.45M 83.88M 76.4M 70.4M 64.04M 120M 7.77B 126M 857M 341M 4.24B 315M 308M 13.32B
Net income -91.28M -83.14M -76.61M -69.69M -131M -8.45B -137M -932M -371M -4.62B -342M -335M -14.49B -34.22M -31.16M -28.72M -26.12M -49M -3.17B -51.5M -350M -139M -1.73B -128M -126M -5.43B
Net Debt - -
Logo Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Inovio Pharmaceuticals Inc